Drug Trial Radar · NCT05586152
Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease
Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
84
Actual
Start
Aug 30, 2022
Primary completion
May 2, 2023
Study completion May 2, 2023
Sponsor
- Lead sponsor
- Invirsa, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Biomedical Advanced Research and Development Authority
- First posted
- Oct 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1/2, first-in-human, 2-part study to assess topically administered eyedrops of INV-102 during 2-week repeat dosing in subjects with moderate symptomatic dry eye disease. Part 1 will be a Dose Escalation phase across 4 cohorts of subjects to assess safety and tolerability of INV-102, and Part 2 will be an Optional Dose Expansion phase in a fifth cohort of subjects, pending the outcome of Part 1, to assess efficacy of INV-102 in the treatment of moderate symptomatic dry eye disease.
Conditions
- Dry Eye Disease
Interventions
INV-102Drug
INV-102 Ophthalmic Solution
VehicleDrug
Vehicle Ophthalmic Solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Subjects With At Least One (1) Treatment-Emergent Adverse EventTime frame: From first dose through study completion (Day 22)
- Part 2: Change From Baseline to Day 15 in the Eye Dryness Score From the Dry Eye Disease (DED) Symptom Visual Analog Scale (VAS)Time frame: Day 15
Locations
1 site in 1 country. Site status is shown where the registry gives one.
iuvo BioScience
Rush, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.